thymalin dosage FAQ

Thymalin should not be stacked with direct immune stimulants like IL-2, interferon-alpha, or high-dose vitamin D during the same injection cycle. The opposing mechanisms (stimulation vs regulation) can cancel each other out. If you're using compounds that modulate immune pathways indirectly. MK-677 for growth hormone secretion or Dihexa for BDNF signalling. Those don't interfere with thymic peptide pathways and can be used concurrently. Avoid combining Thymalin with corticosteroids (prednisone, dexamethasone) or calcineurin inhibitors (tacrolimus, cyclosporine) as those actively suppress the thymic function Thymalin is attempting to regulate.

Do not run Thymalin continuously. Thymic epithelial receptors downregulate under sustained stimulation, and continuous dosing beyond 21 days produces diminishing returns that approach zero by week six regardless of dose escalation. The anti-aging benefit comes from cyclical stimulation followed by rest periods that allow receptor resensitization. A year-round protocol structure would be: 20 days on, 35 days off, repeat four times annually (total: 80 injection days spread across 220 calendar days). Attempting continuous administration wastes peptide, money, and eliminates the regenerative signal the thymus requires to respond.

Use body weight scaling (mg/kg) rather than fixed dosing to maintain proportional peptide exposure. If published research uses 10mg for a 70kg human-equivalent model (approximately 0.14mg/kg), scale that ratio to your subject's actual weight. A 50kg subject would receive 7mg (50kg × 0.14mg/kg), while a 90kg subject would receive 12.6mg (90kg × 0.14mg/kg). This approach maintains consistent peptide concentration relative to body mass and total blood volume, which is particularly important in immune modulation studies where receptor saturation and cytokine signaling are dose-dependent.

Discard the vial immediately. Cloudiness or visible particles indicate contamination, improper reconstitution technique, or peptide aggregation from temperature exposure. Thymalin reconstituted correctly with sterile bacteriostatic water should appear clear and colorless, with no turbidity or particulate matter. Cloudiness most commonly results from injecting bacteriostatic water too forcefully into the vial, creating foam and protein aggregation, or from using water that was not at proper temperature (2-8°C). Never inject a clouded solution. Aggregated peptides do not deliver therapeutic effect and may trigger injection site reactions.

Assume partial or complete loss of bioactivity and do not use that vial for dose-critical research. Peptides are thermolabile. Even 12-16 hours at room temperature (20-25°C) degrades bioactive structure by 20-40%, and that loss is irreversible. The solution may still appear clear and normal, but the thymic peptide components have undergone conformational changes that eliminate immune-modulating function. Replace the compromised vial with a freshly reconstituted dose rather than risk injecting an underdosed or inactive solution that produces uninterpretable study results.

Split the dose across two subcutaneous injection sites rather than attempting a single large-volume injection. Subcutaneous tissue absorption capacity is limited. Volumes above 2mL per site cause localized pooling that delays absorption and reduces peak plasma concentration. If your protocol requires 15mg from a solution reconstituted to 5mg/mL (requiring 3mL total volume), administer 1.5mL at one abdominal site and 1.5mL at a second site on the opposite side or on the thigh. Both injections should occur within the same dosing window (within 5-10 minutes of each other) to maintain consistent pharmacokinetics across the study cohort.

Straight answers on reconstitution, dosing, and safety, everything you need to research with confidence. For research reference only.